拉米夫定对慢性乙型肝炎患者白细胞介素-6和肝纤维化指标的影响

Effect of lamivudine treatment on interleukin-6 and hepatic fibrosis index in chronic hepatitis B patients

目的观察拉米夫定治疗对慢性乙型肝炎患者血清白细胞介素-6(IL-6)和肝纤维化指标的影响。方法 64例慢性乙型肝炎患者随机分为对照组(n=32)和拉米夫定治疗组(n=32),分别在治疗前和治疗后的第6个月用ELISA法检测血清IL-6水平和肝纤维化指标。结果拉米夫定治疗6个月后患者的血清IL-6水平显著低于对照组([84.5±12.6)pg/mL vs(105.7±15.8)pg/mL,P<0.05)],肝纤维化指标血清透明质酸、Ⅳ型胶原和层黏蛋白也明显降低[透明质酸:(172.7±60.7)u/L vs(221.7±71.8)u/L,P<0.05;Ⅳ型胶原:(102.6±47.5)u/L vs(132.6±26.9)u/L,P<0.05;层黏蛋白:(112.2±20.7)u/L vs(139.2±27.2)u/L,P<0.01)]。结论拉米夫定可抑制慢性乙型肝炎患者IL-6的释放,具有抗纤维化的临床疗效。

【Objective】 To investigate the effect of lamivudine on serum interleukin-6（IL-6） levels and hepatic fibrosis indices in patients with chronic hepatitis B（CHB）.【Methods】 A tota1 of 64 patients with CHB were randomized into control group（n =32） and lamivudine treatment group（n =32）.Serum levels of IL-6 and hepatic fibrosis indices were measured with enzyme-linked immunosorbent assay（ELISA） at baseline and 6 months after treatment.【Results】 Lamivudine treatment significantly decreased IL-6 levels [（84.5±12.6） pg/mL vs（105.7±15.8） pg/mL,P 0.05] as well as hepatic fibrosis indices including hyaluronic acid [（172.7±60.7） u/L vs（221.7±71.8） u/L,P 0.05],type Ⅳ collagen [（102.6±47.5） u/L vs（132.6 ±26.9） u/L,P 0.05] and laminin [（112.2±20.7） u/L vs（139.2±27.2） u/L,P 0.01].【Conclusion】 IL-6 levels can be decreased significantly in CHB patients after treated with lamivudine,which may contribute to the anti-fibrosis effects.